WO2009062898A1 - New synthetic arginine substituted peptides and their use - Google Patents

New synthetic arginine substituted peptides and their use Download PDF

Info

Publication number
WO2009062898A1
WO2009062898A1 PCT/EP2008/065186 EP2008065186W WO2009062898A1 WO 2009062898 A1 WO2009062898 A1 WO 2009062898A1 EP 2008065186 W EP2008065186 W EP 2008065186W WO 2009062898 A1 WO2009062898 A1 WO 2009062898A1
Authority
WO
WIPO (PCT)
Prior art keywords
arg
lys
ser
val
ala
Prior art date
Application number
PCT/EP2008/065186
Other languages
French (fr)
Inventor
Inger Mattsby-Baltzer
Gunnar Dolphin
Original Assignee
Pharmasurgics In Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasurgics In Sweden Ab filed Critical Pharmasurgics In Sweden Ab
Priority to AU2008323041A priority Critical patent/AU2008323041A1/en
Priority to JP2010533548A priority patent/JP2011503137A/en
Priority to MX2010005280A priority patent/MX2010005280A/en
Priority to CN200880114504.9A priority patent/CN101878226B/en
Priority to CA2703894A priority patent/CA2703894A1/en
Priority to EP08850370.1A priority patent/EP2212352B1/en
Priority to DK08850370.1T priority patent/DK2212352T3/en
Publication of WO2009062898A1 publication Critical patent/WO2009062898A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations and/or tumours
  • Lactoferrin is a single chain metal-binding glycoprotein with a molecular weight of 77 kd. It has been found that the structural domain of lactoferrin responsible for the bactericidal properties is a pepsin-cleaved fragment called lactoferricin (see e g Bellamy W., et al., Identification of the bactericidal domain of lactoferrin, Biochim.
  • Lactoferrin receptors are found on many types of cells including monocytes and macrophages, lectin-stimulated human peripheral blood lymphocytes, brushborder cells, and tumour cell lines
  • lactoferrin for treatment of infections or inflammations
  • lactoferrin and lactoferricin can be used for treatment and prevention of infections, inflammations and tumours.
  • EP 629 347 describes an antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of antimicrobial peptides derived from lactofemns, and (B) one or more compounds selected from the group consisting of metal-chelating protein, tocopherol, cyclodextrin, glycerine-fatty acid ester, alcohol EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof.
  • This antimicrobial agent is intended for treatment of products, and especially for safely treating e g food and medicines.
  • JP 7145196 describes the preparation of antibiotic peptides by hydrolysis of lactoferrin The preparation of a peptide corresponding to amino acids 17 to 41 of human lactoferrin is specifically described.
  • JP 8040925 discloses pharmaceutical compositions containing lactoferrin derived peptides and their use in the treatment of cornea damages, especially keratitis. Peptides corresponding to amino acids 17 to 41 , 12 to 58, and 19 to 38, of human lactoferrin are specifically disclosed
  • JP 7274970 describes the recombinant production of antibacterial lactoferricin derived peptides, specifically a peptides corresponding to amino acids 18 to 42 of human lactoferrin is disclosed.
  • JP 8143468 describes lactoferrin derived peptides and their use as antiulcer drugs, a peptide corresponding to amino acids 19 to 33 of human lactoferrin is specifically disclosed
  • WO 00/01730 describes peptides derived from human lactoferrin and their use for treatment of infections and inflammations
  • EP 1 228 097 describes peptides derived from the immediate N-terminal end of human lactoferrin and their use as microbial agents.
  • EP 1151009 describes peptides comprising a sequence corresponding to amino acids 35 to 50 of human lactoferrin having antimicrobial and/or endotoxin neutralizing activity
  • WO 2006/047744 describes immunomodulatory peptides derived from the N-terminal part of human lactoferrin comprising at least 33 amino acids and being substituted in both the N- and C-terminus with four positively charged amino acids
  • the object of the present invention is to provide new synthetic peptides which can be used for the same purposes as lactoferrin, lactoferricin or other lactoferrin derived peptides and which will have the same, or better, effects although having production, technical and/or biochemical advantages
  • the aim of the studies leading to the present invention was to design new peptides which should essentially be as efficient as, or preferably more efficient, than human lactoferrin, human lactoferricin and other lactoferrin derived peptides in treatment and prevention of infections, inflammations, tumours, wounds, and scars.
  • the peptides designed based on the sequence constituted of amino acids 21-31 from the N-terminal end of human lactoferrin, substituted with arginine containing peptides have the desired properties.
  • the present invention relates to new synthetic peptides and to functionally equivalent homologues or analogues thereof. Furthermore, the invention relates to medicinal products and to food stuff, especially infant formula food, comprising said peptides.
  • the invention also relates to use of said peptides for the production of medicinal products for treatment and prevention of infections, inflammations and tumours
  • the peptides according to the invention are fungicidal and bactericidal, and can thus be used for other applications when substances with such properties are desired. They may for example be used as preservatives
  • the present invention relates to peptides designed based on the amino acid sequence of fragments of the protein human lactoferrin (hLF).
  • the fragment of hLF that is used as a basis for the invention is constituted by the amino acids in positions 21-31 of hl_F, the sequence of which is:
  • Ac and NH 2 in some of the sequences denote an acetyl (CH 3 CO-) group and an amino group, respectively, that have been used to modify the amino and the carboxy terminals of the peptides.
  • the N-terminal part of human lactoferrin contains an arginine rich sequence, as shown below for the sequence of amino acids 1-31 of human lactoferrin:
  • the sequence Gly-Arg-Arg-Arg-Arg-Ser was identified as an important sequence motif and was used in the design of the peptides of the invention.
  • the present invention relates to peptides according to formula (I)
  • R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 3 and N-terminally truncated fragments thereof including
  • R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 1 1 and N-terminally truncated fragments thereof including
  • Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys Cys-Ala-Val-Ser-GIn-Pro-Glu-Ala-Thr-Lys-Cys,
  • R2 is either no amino acid, Pro or a peptide sequence selected from SEQ ID NO:4 and C-terminally truncated fragments thereof including
  • X8 is GIy and R3 is Ser-(Arg) n -X9 and the bond ⁇ is a peptide bond between the carboxyl group of GIy and the amino group of Ser.
  • X8 is Lys and R3 is X9-(Arg) n -Ser and the bond ⁇ is an amide bond between the ⁇ -amino group in Lys and the carboxyl group in Ser.
  • X8 is GIu and R3 is Ser-(Arg) n -X9 and the bond ⁇ is an amide bond between the ⁇ -carboxyl group of GIu and the amino group of Ser.
  • amino acid X1 is GIn
  • X2 is Trp
  • X3 is GIn or Lys
  • X4 is Arg
  • X5 is Asn or Ala
  • X6 is Met
  • X7 is Arg.
  • R1 is either no amino acid or the peptide sequence Ala-Thr-Lys-Cys.
  • R2 is either no amino acid or the peptide sequence Pro-Pro-Val-Ser-Cys-lle-Lys-Arg.
  • the present invention provides purified peptides comprising SEQ ID NO: 12 (Phe-Gln-Trp-X3-Arg-X5-Met-Arg-I_ys-Val-Arg-Gly-Ser- Arg-Arg-Arg-Gly), wherein X3 is GIn or Lys and X5 is Asn or Ala, and wherein the peptide is SEQ ID NO: 5, 6, 7, 8, 9, or 10.
  • the carboxy terminal end of the peptide has been capped, i. e. the free COOH at the carboxy terminal end has been transformed into CONH 2 .
  • the amino terminal end of the peptide has been capped, i. e. the free NH 2 group at the amino terminal end has been transformed into the amide CH 3 CONH- (AcNH-).
  • the peptides When the peptides are branched one or both of the amino terminal ends of the peptide can be capped. When the peptides are branched one or both of the carboxy terminal ends of the peptide can be capped.
  • both the carb ⁇ xy-terminal and the ami ⁇ o-terminal ends of the peptide have been capped.
  • the advantage of the capped versions is that N- and C-terminal amino acids of these peptides are neutral and uncharged and thus has changed electrostatic properties. Assuming that the receptors bind the corresponding sequences of human lactoferrin where there are no N- and C terminal charges, the capped peptides should bind better as they in this respect resemble the native protein more than uncapped peptides.
  • Preferred peptides of the invention are:
  • CysM is acetamidomethyl-cysteme
  • N-terminally and/or C-terminally un-capped form of a peptide has been given, it is also possible, according to the invention, to use the capped forms.
  • the peptides according to the invention are therefore an important part of the peptides according to the invention.
  • the advantage of the peptides according to the invention is that they comprise the part of the lactoferricin fragment of the human lactoferrin protein, or a modified version thereof, which the inventors have found to be active with regards to the invention
  • the peptides according to the invention are suitable for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars.
  • treatment used herein refers to curing, reversing, attenuating, alleviating, minimising, suppressing or halting the deleterious effects of a disease state, disease progression or other abnormal condition
  • prevention used herein refers to minimising, reducing or suppressing the risk of developing a disease state or progression or other abnormal or deleterious conditions.
  • the infections treatable with the peptides or medicinal products according to the invention include infections caused by all kinds of pathogens, such as bacteria, viruses, fungi, etc It is also possible to treat different types of inflammations Inflammation is a complex phenomenon marked i a by abnormal "redness" and swelling of tissues and organs, pain and heat in affected areas, capillary dilation, leucocyte infiltration, etc. Inflammation is primarily caused by exposure to bacterial and other noxious agents and physical injury. Inflammation has many forms and is mediated by a variety of different cytokines and other chemical signals.
  • TNF- ⁇ tumour necrosis factor- ⁇
  • IL-1 interleuk ⁇ n-1
  • IL-6 ⁇ nterleuk ⁇ n-6
  • IL-8 ⁇ nterleuk ⁇ n-8
  • CSFs colony-stimulating factors
  • the peptides according to the invention are also suitable for treatment of tumours
  • the peptides according to the invention may either be used as they are or be included in a medicinal product or a pharmaceutical preparation
  • the medicinal product or a pharmaceutical preparation according to the invention may also comprise substances used to facilitate the production of the pharmaceutical preparation or the administration of the preparations.
  • substances are well known to people skilled in the art and may for example be pharmaceutically acceptable adjuvants, carriers and preservatives.
  • the peptides according to the invention may either be formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.
  • the peptides or medicinal products according to the invention can be administered to a patient either orally, systemically, parenteral ⁇ , locally or topically.
  • patient used herein relates to any person at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition.
  • the systemic administration is suitable e. g. for treatment of urinary tract infection, colitis and tumours.
  • the systemic administration can be undertaken by oral, nasal, intravenous, intraartery, intracavitary, intramuscular, subcutaneous, transdermal, suppositories (including rectal) or other routes known to those of skill in the art. Oral administration is preferred.
  • the local administration is suitable e g.
  • the local administration can be undertaken by topical, oral, nasal, vaginal or oropharyngeal route
  • the peptides or medicinal products according to the invention may e. g. be included in a gel, a cream, an ointment, or a paste.
  • an effective amount of a peptide according to the invention is administered to a patient.
  • the term "effective amount” used herein relates to an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious conditions.
  • the peptides or medicinal products and methods according to the invention are particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by fungi, e.g. Candida species such as Candida albicans and Candida krusei, Aspergillus and Cryptococcus neoformans.
  • Candida species such as Candida albicans and Candida krusei, Aspergillus and Cryptococcus neoformans.
  • the peptides, medicinal products and methods according to the invention are also well suited for preventive medical care by reducing the risk of developing urinary tract infection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications.
  • the peptides of the present invention are suited for are anti-inflammatory and immunomodulatory therapies, exemplified but not limited to:
  • Nervous system Nervous system; Alzheimer, Multiple Sclerosis, Carpal tunnel syndrome, Disc herniation, Cervical rhizopathy, Bells palsy, Acute spinal cord injury, Spinal cord compression, Spinal stenosis, Postherpetic neuralgia, Viral encephalitis, Viral meningitis, Menieres disease, Polio and postpolio complications, Chronic
  • the peptides of the invention are further suited for prevention and treatment of wounds and scars in connection with conditions and procedure, exemplified but not limited to:
  • the peptides of the invention have anti-infectious effects, and are suited for the prevention and treatment of:
  • Genital tract including vaginosis, vaginitis, cervicitis, endometritis, PID
  • Gastrointestinal tract infections systemic infections initiated in the Gl
  • Upper and lower respiratory tract such as aphthae, mucocutanous candidiasis
  • Genitourinary tract such as vulvovaginal candidiasis, balanitis
  • Gastrointestinal tract infections systemic infections initiated in the Gl
  • peptides, medicinal products and methods according to the invention may either be used alone, in combination with each other or in combination with conventional therapy.
  • the present invention it is also possible to include the peptides, in an effective amount, in any kind of food or beverage intended to reduce infections and/or inflammations in patients running an increased risk of such conditions due to an underlying disease, a low birth weight or a medical treatment.
  • the peptides in an effective amount, in an infant formula food intended to inhibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants.
  • the peptides according to the invention is to be used in food stuffs, e. g. for nutritional purposes, it is especially preferred to use peptides of natural origin.
  • the peptides according to the invention have antimicrobial effects they can also be used as preservatives in different food stuffs and medicinal products such as gels, creams, ointments, pastes, solutions, emulsions etc.
  • FIG. 1 Growth inhibition of E.coli ' m the presence of HLBDargi and a 23-a.a. long peptide (amino acids 18 to 40 of hl_F). Using a peptone medium (1%) the microplate was incubated over night and read spectrophotometrically at 650 nm. As can be seen a concentration of 12.5 ⁇ g/ml totally reduced the growth.
  • Figure 2. A) The number of S. aureus located in the joints of peptide-treated and vehicle treated animals. B) The distribution of animals with a scoring of 3 or more (the most severe inflammation and/or erosion of joint tissue was scored as 5, and no histological changes as 0). A dose of 2x10" S.aureus and 100 ⁇ g of peptide (HLBDargi) were injected.
  • Arg-Arg-Arg-Arg-Arg- or Arg-Arg-Arg-containing peptides (Table 1) have been analysed by an antimicrobial assay using E.coli, S.aureus and C.albicans as test microorganisms.
  • Washed cells were suspended in 1 % Bactopeptone (BP)(Difco, USA). The concentration of bacterial or fungal cells was spectrophotometrically adjusted. Peptides serially diluted in BP by twofold steps were added in duplicate or triplicate to the wells of a microtiterpiate (200 ⁇ l per well). The bacterial or yeast cell solutions were added in 10 ⁇ l volumes to give a final concentration of approximately 2 x 10 5 cells per ml. The concentration of the stock solution was always checked by viable counts. The microplate was incubated at 37 0 C in a humid chamber for 2 h unless otherwise stated. Five ⁇ l were taken from each well and added as a drop onto a blood agar plate and incubated over night at 37°C.
  • BP Bactopeptone
  • the concentration of lactoferrin or peptide causing a 99% reduction of the inoculum was defined as the MMC 99 .
  • HLBD31 natural sequence amino acids 1-31
  • HLBDarg2 HLBDarg2
  • Arg-Arg-Arg-Arg-Arg sequence was linked to phenylalanine from the amino-terminal side via a spacer (three glycine residues).
  • Cm is acetamidomethyl-cysteine
  • mice 5 to 8-week old mice were obtained from B&K (Sollentuna, Sweden) and 30 maintained in the animal facility of the Department of Rheumatology, University of G ⁇ teborg. They were housed 10 per cage under standard conditions of temperature, and light and fed standard chow and water ad libitum.
  • S. aureus strain AB-1 Bacterial strain and infection.
  • S. aureus strain AB-1 was used. The bacteria were injected into the both knee joints (synovial space) of the hind paw. Immediately before
  • Candida albicans The yeast cells (ATCC64549) were incubated over night in Sabourad broth at 23 0 C. The cells were washed in phosphate buffer (10 mM, pH 7.4) and adjusted to a concentration of 2x10 10 ZmI.
  • mice were treated with C. albicans on a shaved area (2x10 s yeast cells per spot) by gentle rubbing a volume of 10 ⁇ l with a blunt plastic rod during anaesthesia.
  • anaesthetized mice were treated with 10 or 20 ⁇ l of a peptide solution or vehicle (phosphate buffer) by applying the volume onto the infected spots.
  • the solution was allowed to dry. After 4 h the treatment was repeated. The day after the animals were killed. Viable counts were performed on washings, obtained from the treated areas by using a metal ring placed over the spot and gentle rubbing in the presence of 100 ⁇ l of phosphate buffer containing Triton-x 100 (0.01%).
  • HLBDargi 3 40 ⁇ 10 166 ⁇ 33 0.0066 HLBDargirak 2 105 ⁇ 28 414 ⁇ 60 0.0004 HLBDarg ⁇ 1 12 ⁇ 8.3° 43+3 0.024 ° 1 mg per spot
  • the MeT- 5A cell line corresponding to normal human mesothelial cells was maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF; AMS Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA Laboratories GmbH) and 870 nM human recombinant insulin (Sigma).
  • the cells were induced by addition of recombinant IL-1 (R&D Systems), 0.1 or 0.5 ng/ml in the case of the IL-6 or PAI- 1 assay, respectively, into the medium specified above except of containing 5% heat inactivated FBS.
  • the given concentration of peptide HLBD1 Arg rak was added immediately after stimulation by IL-1
  • IL-6 production was measured 3 hours after induction by quantitative immunoassay ELISA using human monoclonal anti-IL-6 antibody (R&D Systems).
  • PAI-1 levels were measured 6 hours after induction by commercially available ELISA kit (Tint-Eliza PAI-1 , Trinity Biotech).
  • the THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was maintained in RPM1 1640 (PAA Laboratories GmbH) supplemented with 10% fetal bovine serum (FBS 1 PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES (PAA).
  • the cell density was adjusted to 1 x10 6 cells/ml and 500 ⁇ l of the cell suspension was added to 24-well cell culture plates (Sarstedt)
  • the cells were treated with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48 hours to differentiate the monocytes into macrophage-like cells. After 48 hours the cells were stimulated by addition of 0.1 ng/ml LPS (E.
  • Example 6 In vitro anti-inflammatory and fibrinolytic effect
  • the MeT-5A cell line corresponding to normal human mesothelial cells was maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum (FBS 1 PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF, AMS Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA Laboratories GmbH) and 870 nM human recombinant insulin (Sigma).
  • the cell density was adjusted to 1.6x10 5 cells/ml and 100 ⁇ l of the cell suspension was added per well to 96-well cell culture plates (Sarstedt).
  • the cells were incubated for 48 hours to allow cells to attach and grow to confluence. After 48 hours the cells were induced by addition of recombinant IL-1 ⁇ (R&D Systems), 0 1 or 0 5 ng/ml in the case of the IL-6 or PAI-1 assay, respectively, into the medium specified above except of containing 5% heat inactivated FBS The given concentrations of the different peptides were added immediately after stimulation by I L- 1 ⁇
  • the cell supernatants were collected after 3 or 6 hours of incubation and analyzed for IL-6 or PAI-1 by ELISAs specific for IL-6 (R&D Systems) or for PAI-1 (Tint-Eliza PAI-1 , Trinity Biotech), respectively
  • Example 7 In vitro anti-inflammatory effect The THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was maintained in RPMI 1640 (PAA Laboratories GmbH) supplemented with 10% fetal bovine serum (FBS, PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES (PAA) The cell density was adjusted to 1x10 e cells/ml and 100 ⁇ l of the cell suspension was added per well to 96-well cell culture plates (Sarstedt) The cells were treated with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48 hours to differentiate the monocytes into macrophage-like cells After 48 hours the cells were stimulated by addition of 0 1 ng/ml LPS (E coll serotype 055 B5; Sigma) into the medium specified above except of containing 5% heat inactivated FBS The indicated concentrations of the different peptides were added 30 mm after addition of LPS The cell supern
  • Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg- or Arg-Arg-Arg-Arg-Arg- containing peptides have been analysed by an antimicrobial assay using E.coli, S.aureus and P. aeruginosa as test microorganisms.
  • Cells were suspended in 1% Brain-heart infusion medium (BHI)(Difco, USA). The concentration of bacterial cells was spectrophotometrically adjusted.
  • Peptides serially diluted in 1% BHI by twofold steps were added in duplicate to the wells of a microtiterplate (100 ⁇ l per well). The bacterial solutions were added in 5 ⁇ l volumes to give a final concentration of approximately 5 x 10 5 cells per ml.
  • the concentration of the stock solution was always checked by viable counts.
  • the microtiterplate was incubated at 37°C for two hours. Five ⁇ l were taken from each well and added as a drop onto a blood agar plate and incubated over night at 37 C C.
  • the concentration of peptide causing a 99% reduction of the inoculum was defined as the MMC 99 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.

Description

NEW SYNTHETIC ARGININE SUBSTITUTED PEPTIDES AND THEIR USE
Field of the invention
The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations and/or tumours
Background art
Lactoferrin is a single chain metal-binding glycoprotein with a molecular weight of 77 kd. It has been found that the structural domain of lactoferrin responsible for the bactericidal properties is a pepsin-cleaved fragment called lactoferricin (see e g Bellamy W., et al., Identification of the bactericidal domain of lactoferrin, Biochim. Biophys Acta 1121 130-136, 1992, and Bellamy W , et al , Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin, J Appl Bact 73 472-479, 1992) Lactoferrin receptors are found on many types of cells including monocytes and macrophages, lectin-stimulated human peripheral blood lymphocytes, brushborder cells, and tumour cell lines
Several patent publications describe the possible use of lactoferrin for treatment of infections or inflammations In WO 98/06425, e g , it is disclosed that lactoferrin and lactoferricin can be used for treatment and prevention of infections, inflammations and tumours.
EP 629 347 describes an antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of antimicrobial peptides derived from lactofemns, and (B) one or more compounds selected from the group consisting of metal-chelating protein, tocopherol, cyclodextrin, glycerine-fatty acid ester, alcohol EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof. This antimicrobial agent is intended for treatment of products, and especially for safely treating e g food and medicines. The agent according to this publication is thus a new preservative In the publication several peptide sequences are given and some of them resemble the peptides according to the invention, although there are several important differences described further below US 5,304,633 discloses antimicrobial peptides isolated from hydrolysates of human and bovine lactoferrin Isolation of peptides corresponding to amino acids 12 to 47, and 17 to 41 of human lactoferrin are specifically disclosed
JP 7145196 describes the preparation of antibiotic peptides by hydrolysis of lactoferrin The preparation of a peptide corresponding to amino acids 17 to 41 of human lactoferrin is specifically described.
JP 8040925 discloses pharmaceutical compositions containing lactoferrin derived peptides and their use in the treatment of cornea damages, especially keratitis. Peptides corresponding to amino acids 17 to 41 , 12 to 58, and 19 to 38, of human lactoferrin are specifically disclosed
JP 7274970 describes the recombinant production of antibacterial lactoferricin derived peptides, specifically a peptides corresponding to amino acids 18 to 42 of human lactoferrin is disclosed.
JP 8143468 describes lactoferrin derived peptides and their use as antiulcer drugs, a peptide corresponding to amino acids 19 to 33 of human lactoferrin is specifically disclosed
WO 00/01730 describes peptides derived from human lactoferrin and their use for treatment of infections and inflammations
EP 1 228 097 describes peptides derived from the immediate N-terminal end of human lactoferrin and their use as microbial agents.
EP 1151009 describes peptides comprising a sequence corresponding to amino acids 35 to 50 of human lactoferrin having antimicrobial and/or endotoxin neutralizing activity
WO 2006/047744 describes immunomodulatory peptides derived from the N-terminal part of human lactoferrin comprising at least 33 amino acids and being substituted in both the N- and C-terminus with four positively charged amino acids
Summary of the invention
The object of the present invention is to provide new synthetic peptides which can be used for the same purposes as lactoferrin, lactoferricin or other lactoferrin derived peptides and which will have the same, or better, effects although having production, technical and/or biochemical advantages The aim of the studies leading to the present invention was to design new peptides which should essentially be as efficient as, or preferably more efficient, than human lactoferrin, human lactoferricin and other lactoferrin derived peptides in treatment and prevention of infections, inflammations, tumours, wounds, and scars. It was found that peptides formed of the sequences constituted of all or some of the amino acids 21-31 of human lactoferrin counted from the N-terminal end, further substituted with arginine containing peptides, have the desired properties.
According to the present invention, it is shown that the peptides designed based on the sequence constituted of amino acids 21-31 from the N-terminal end of human lactoferrin, substituted with arginine containing peptides, have the desired properties.
It has been shown that humans in their brush border membrane have receptors which can bind to human lactoferrin (see e. g. Lonnerdal B., Lactoferrin receptors in intestinal brush border membranes, Adv Exp. Med. Biol. 1994, 357: 171-175) It has also been shown that bovine lactoferrin does not bind to these receptors. A plausible mechanism for the uptake of these new peptides in the human body is that the peptides are taken up through binding to cellular receptors. However, the invention is in no way limited to this mechanism
Thus, the present invention relates to new synthetic peptides and to functionally equivalent homologues or analogues thereof. Furthermore, the invention relates to medicinal products and to food stuff, especially infant formula food, comprising said peptides.
The invention also relates to use of said peptides for the production of medicinal products for treatment and prevention of infections, inflammations and tumours
The peptides according to the invention are fungicidal and bactericidal, and can thus be used for other applications when substances with such properties are desired. They may for example be used as preservatives
The characterising features of the invention will be evident from the following description and the appended claims.
Detailed description of the invention
Thus, the present invention relates to peptides designed based on the amino acid sequence of fragments of the protein human lactoferrin (hLF). The fragment of hLF that is used as a basis for the invention is constituted by the amino acids in positions 21-31 of hl_F, the sequence of which is:
Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg (SEQ ID NO: 1)
In the description single-letter or three-letter symbols are used to denote the amino acids. These symbols, which are well known to man skilled in the art, have the following meaning: A = Ala = alanine, C = Cys = cysteine, D = Asp = aspartic acid, E = GIu = glutamic acid, F = Phe = phenylalanine, G= GIy = glycine, I- He = isoleucine, K = Lys = lysine, M= Met = methionine, N = Asn = asparagine, P = Pro = proline, Q = GIn = glutamine, R = Arg = arginine, S = Ser = serine, T = Thr = threonine, V = VaI = valine, W = Trp = tryptophan, Orn = Ornithine, NIe = Norleucine and X = Xaa = a variable amino acid. Ac and NH2 in some of the sequences denote an acetyl (CH3CO-) group and an amino group, respectively, that have been used to modify the amino and the carboxy terminals of the peptides. The N-terminal part of human lactoferrin contains an arginine rich sequence, as shown below for the sequence of amino acids 1-31 of human lactoferrin:
Gly-Arg-Arg-Arg-Arg-Ser-Val-GIn-Trp-Cys-Ala-Val-Ser-GIn-Pro-Glu-Ala-Thr-Lys-Cys- -Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg (SEQ ID NO:2)
The sequence Gly-Arg-Arg-Arg-Arg-Ser was identified as an important sequence motif and was used in the design of the peptides of the invention.
The present invention relates to peptides according to formula (I)
R1 -Phe-X1 -X2-X3-X4-X5-X6-X7-Lys-Val-Arg-X8-R2
| α R3 Formula (I) wherein amino acid X1 is GIn or Ala, amino acid X2 is Trp or Leu, amino acid X3 is GIn, Ala, Om, NIe or Lys, amino acid X4 is Arg, Ala or Lys, amino acid X5 is Asn, Ala, Om or NIe, amino acid X6 is Met, Ala or Leu, amino acid X7 is Arg, Ala or Lys, amino acid X8 is GIy, Lys, GIu or Asp; when X8 is GIy then R3 is Ser-(Arg)n-X9 and the bond α is a peptide bond between the carboxyl group of GIy and the amino group of Ser; when X8 is Lys then R3 is X9-(Arg)n-Ser and the bond α is an amide bond between the ε-amino group in Lys and the carboxyl group in Ser; and when X8 is GIu or Asp then R3 is Ser-(Arg)n-X9 and the bond α is an amide bond between the γ-carboxyl group of GIu or the β-carboxyl group of Asp and the amino group of Ser; amino acid X9 is either no amino acid or GIy; and n is an integer from 1 to 10, preferably an integer from 2 to 6, preferably an integer from 4 to 6, or even more preferably an integer from 3 to 4;
R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 3 and N-terminally truncated fragments thereof including
Gly-Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys, Arg-Arg-Arg-Arg-Ser- VaI-G In-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Glπ-Pro-Glu-Ala-Thr-Lys-Cys, Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Cys-Ala-Val-Ser-Glπ-Pro-Glu-Ala-Thr-Lys-Cys,
Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys, Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Pro-Glu-Ala-Thr-Lys-Cys,
Glu-Ala-Thr-Lys-Cys, Ala-Thr-Lys-Cys,
Thr-Lys-Cys, and
Lys-Cys,
Preferably R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 1 1 and N-terminally truncated fragments thereof including
Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys, Cys-Ala-Val-Ser-GIn-Pro-Glu-Ala-Thr-Lys-Cys,
Ala-Val-Ser-GIn-Pro-Glu-Ala-Thr-Lys-Cys,
Val-Ser-GIn-Pro-Glu-Ala-Thr-Lys-Cys,
Ser-GIn-Pro-Glu-Ala-Thr-Lys-Cys, Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Pro-Glu-Ala-Thr-Lys-Cys,
Glu-Ala-Thr-Lys-Cys,
Ala-Thr-Lys-Cys,
Thr-Lys-Cys, and
Lys-Cys,
R2 is either no amino acid, Pro or a peptide sequence selected from SEQ ID NO:4 and C-terminally truncated fragments thereof including
Pro-Pro-Val-Ser-Cys-lle-Lys-Arg, Pro-Pro-Val-Ser-Cys-lle-Lys,
Pro-Pro-Val-Ser-Cys-lle,
Pro-Pro-Val-Ser-Cys,
Pro-Pro-Val-Ser,
Pro-Pro-Val, and Pro-Pro;
The above peptide sequences defining R2 thereby being represented by SEQ ID NO: 4 or C-terminally truncated fragments thereof.
In one preferred embodiment X8 is GIy and R3 is Ser-(Arg)n-X9 and the bond α is a peptide bond between the carboxyl group of GIy and the amino group of Ser. In another preferred embodiment X8 is Lys and R3 is X9-(Arg)n-Ser and the bond α is an amide bond between the ε-amino group in Lys and the carboxyl group in Ser.
In another preferred embodiment X8 is GIu and R3 is Ser-(Arg)n-X9 and the bond α is an amide bond between the γ-carboxyl group of GIu and the amino group of Ser.
In other preferred embodiments amino acid X1 is GIn, X2 is Trp, X3 is GIn or Lys, X4 is Arg, X5 is Asn or Ala, X6 is Met, and/or X7 is Arg.
In another preferred embodiment R1 is either no amino acid or the peptide sequence Ala-Thr-Lys-Cys. In yet another preferred embodiment R2 is either no amino acid or the peptide sequence Pro-Pro-Val-Ser-Cys-lle-Lys-Arg.
In one preferred embodiment the present invention provides purified peptides comprising SEQ ID NO: 12 (Phe-Gln-Trp-X3-Arg-X5-Met-Arg-I_ys-Val-Arg-Gly-Ser- Arg-Arg-Arg-Arg-Gly), wherein X3 is GIn or Lys and X5 is Asn or Ala, and wherein the peptide is SEQ ID NO: 5, 6, 7, 8, 9, or 10.
When present, it may be advantageous to replace the amino acid Cys by an acetamidomethyl-cysteine in order to avoid that the peptide forms a disulphide bridge with another peptide comprising a cysteine, and/or an intermolecular disulphide bridge if the peptide comprises two Cys residues.
According to one preferred aspect of the invention the carboxy terminal end of the peptide has been capped, i. e. the free COOH at the carboxy terminal end has been transformed into CONH2. According to another preferred aspect of the invention the amino terminal end of the peptide has been capped, i. e. the free NH2 group at the amino terminal end has been transformed into the amide CH3CONH- (AcNH-).
When the peptides are branched one or both of the amino terminal ends of the peptide can be capped. When the peptides are branched one or both of the carboxy terminal ends of the peptide can be capped.
According to yet another preferred aspect of the invention both the carbσxy-terminal and the amiπo-terminal ends of the peptide have been capped.
The advantage of the capped versions is that N- and C-terminal amino acids of these peptides are neutral and uncharged and thus has changed electrostatic properties. Assuming that the receptors bind the corresponding sequences of human lactoferrin where there are no N- and C terminal charges, the capped peptides should bind better as they in this respect resemble the native protein more than uncapped peptides.
Preferred peptides of the invention are:
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2 I
Gly-Arg-Arg-Arg-Ser; Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-Nh^
I Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-GIn-Trp-GIn-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NHz
I Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Tφ-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2 I
Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2
I Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2
I Ac-Gly-Arg-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2
I Ac-Gly-Arg-Arg-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2 I
Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ac-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg -GIy-NH2; Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-GIn-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg
I Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg
I Gly-Arg-Arg-Arg-Arg-Ser;
Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2
I Gly-Arg-Arg-Arg-Arg-Ser;
Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg
I Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg
I Gly-Arg-Arg-Arg-Arg-Ser;
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg-NH2 I
Ac-G ly-Arg-Arg-Arg-Arg-Arg-Ser
Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2 I
Gly-Arg-Arg-Arg-Arg-Ser;
Ala-Thr-Lys-CysM- -Phe-GIn-Trp-GIn-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ac-Phe-Gln-Trp-Glπ-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg I
Ser-Arg-Arg-Arg-Arg-Gly-NH2; Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NHz
I
Ser-Arg-Arg-Arg-Arg-Arg-Arg-Gly-NH2
Ala-Thr-Lys-CysM- -Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NI-k
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
Ac-Phe-Gln-Trp-Gln-Arg-Asπ-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH∑; (SEQ ID NO: 5)
Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-GIn-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NHa;
(SEQ ID NO: 6)
Ac-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH2;
(SEQ ID NO: 7)
Ala-Thr-Lys-CysM- -Phe-Gln-Trp-Lys-Arg-Asπ-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH2;
(SEQ ID NO: 8)
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NHj;
(SEQ ID NO: 9) Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH2;
(SEQ ID NO: 10) CysM is acetamidomethyl-cysteme Where the N-terminally and/or C-terminally capped form of a peptide has been given, it is also possible, according to the invention, to use the un-capped forms.
Where the N-terminally and/or C-terminally un-capped form of a peptide has been given, it is also possible, according to the invention, to use the capped forms.
The sequences Gly-Arg-Arg-Arg-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Arg-Arg-Ser, Gly-Arg-Arg-Arg-Ser, Ser-Arg-Arg-Arg-Arg-Arg-Arg-Gly, Ser-Arg-Arg-Arg-Arg-Arg-Gly and Ser-Arg-Arg-Arg-Arg-Gly are positively charged under physiological conditions and are capable of strong and specific interactions with receptors. They are therefore an important part of the peptides according to the invention The advantage of the peptides according to the invention is that they comprise the part of the lactoferricin fragment of the human lactoferrin protein, or a modified version thereof, which the inventors have found to be active with regards to the invention
In some cases only the capped form of a sequence has been given in the appended sequence listing. However, it is also possible, according to the invention, to use the non-capped forms.
Further substitution of active fragments of hLF with an Arg containing peptide resulting in the peptides of the present invention has been shown to provide peptides with improved properties compared to other known peptides derived from hLF.
The peptides according to the invention are suitable for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars. The term "treatment" used herein refers to curing, reversing, attenuating, alleviating, minimising, suppressing or halting the deleterious effects of a disease state, disease progression or other abnormal condition, and the term "prevention" used herein refers to minimising, reducing or suppressing the risk of developing a disease state or progression or other abnormal or deleterious conditions.
The infections treatable with the peptides or medicinal products according to the invention include infections caused by all kinds of pathogens, such as bacteria, viruses, fungi, etc It is also possible to treat different types of inflammations Inflammation is a complex phenomenon marked i a by abnormal "redness" and swelling of tissues and organs, pain and heat in affected areas, capillary dilation, leucocyte infiltration, etc. Inflammation is primarily caused by exposure to bacterial and other noxious agents and physical injury. Inflammation has many forms and is mediated by a variety of different cytokines and other chemical signals. These mediators of inflammation include tumour necrosis factor-α (TNF-α), interleukιn-1 (IL-1), ιnterleukιn-6 (IL-6), ιnterleukιn-8 (IL-8), and various colony-stimulating factors (CSFs).
As stated above, the peptides according to the invention are also suitable for treatment of tumours
The peptides according to the invention may either be used as they are or be included in a medicinal product or a pharmaceutical preparation The medicinal product or a pharmaceutical preparation according to the invention may also comprise substances used to facilitate the production of the pharmaceutical preparation or the administration of the preparations. Such substances are well known to people skilled in the art and may for example be pharmaceutically acceptable adjuvants, carriers and preservatives.
The peptides according to the invention may either be formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.
The peptides or medicinal products according to the invention can be administered to a patient either orally, systemically, parenteral^, locally or topically. The term "patient" used herein relates to any person at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition. The systemic administration is suitable e. g. for treatment of urinary tract infection, colitis and tumours. The systemic administration can be undertaken by oral, nasal, intravenous, intraartery, intracavitary, intramuscular, subcutaneous, transdermal, suppositories (including rectal) or other routes known to those of skill in the art. Oral administration is preferred. The local administration is suitable e g. for treatment of skin infections, all infections and inflammations in mucosal membranes etc The local administration can be undertaken by topical, oral, nasal, vaginal or oropharyngeal route For treatment of local infections or inflammations in the skin or mucosal membranes the peptides or medicinal products according to the invention may e. g. be included in a gel, a cream, an ointment, or a paste.
In the method according to the invention an effective amount of a peptide according to the invention is administered to a patient. The term "effective amount" used herein relates to an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious conditions.
The peptides or medicinal products and methods according to the invention are particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by fungi, e.g. Candida species such as Candida albicans and Candida krusei, Aspergillus and Cryptococcus neoformans. This listing is in no way limiting the scope of the invention. The peptides, medicinal products and methods according to the invention are also well suited for preventive medical care by reducing the risk of developing urinary tract infection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications.
The peptides of the present invention are suited for are anti-inflammatory and immunomodulatory therapies, exemplified but not limited to:
1) Generally, treatment of inflammation and/or medical condition resulting from inflammation, and specifically,
2a) Intestine; Morbus Crohn, Colitis, Ulcerative colitis,
2b) Joints; Rheumatoid arthritis, Arthritis, Arthrosis, Localized disorders of muscles including muscle spasm, muscle tear, muscle injury, muscle strain, muscle sprain,
2c) Dermatology; Psoriasis, Eczema (excema), Dermatitis, Acne
2d) Heart; Pericarditis, Endocarditis Cardiac insufficiency,
2e) Pain; (further specified under 2f below).
2f) Nervous system; Alzheimer, Multiple Sclerosis, Carpal tunnel syndrome, Disc herniation, Cervical rhizopathy, Bells palsy, Acute spinal cord injury, Spinal cord compression, Spinal stenosis, Postherpetic neuralgia, Viral encephalitis, Viral meningitis, Menieres disease, Polio and postpolio complications, Chronic
Inflammatory Demyeliπating Polyneuropathy, Polyneuropathy, Trigminal neuralgia,
Chronic epileptic disorders, 2g) Sensory organs; Glaucoma
2h) Mucosal surfaces (inflammation as a result of chemo/radiation therapy),
2i) Allergy,
2j) Autoimmune diseases The peptides of the invention are further suited for prevention and treatment of wounds and scars in connection with conditions and procedure, exemplified but not limited to:
3a) surgical procedures on various tissues such as skin, muscles, tendons, nervous tissue, blood vessels, and at different locations of the body such as eyes, ears, vocal cord, hand, spinal cord, intra-abdominal cavity, intra-thoracic cavity, intra-cranial cavity, oral cavity, gynecological procedures, endometrios, phimosis,
3b) acne
3c) hypertrophic scars & keloids,
3d) pleuritis, 3e) peritoneal dialysis,
The peptides of the invention are further believed to have anti-angiogenetic effects and are therefore suited for treatment of :
4a) Cancer
4b) Rheumatoid arthritis The peptides of the invention have anti-infectious effects, and are suited for the prevention and treatment of:
5a) Antibacterial effects:
Upper and lower respiratory tract (tonsillitis, sinusitis etc.)
Infections of the eye (e.g. conjunctivitis) Urinary tract infections
Sexually transmitted diseases (including antimicrobial coating of condomes)
Genital tract including vaginosis, vaginitis, cervicitis, endometritis, PID
Gastrointestinal tract infections (systemic infections initiated in the Gl)
Central nervous system infections Infections of the skin (including staphylococci, for instance MRSA, nosocomial, wounds, burns), muscle, joints (e.g. septic arthritis), bone and hemopoietic system
Infections related to the mouth, including parodontitis, gingivitis
5b) Antiviral effects:
Upper and lower respiratory tract Sexually transmitted diseases Gastrointestinal tract infections (systemic infections initiated in the Gl) Central nervous system infections 5c) Antifungal effects:
Upper and lower respiratory tract (such as aphthae, mucocutanous candidiasis) Genitourinary tract, such as vulvovaginal candidiasis, balanitis,
Gastrointestinal tract infections (systemic infections initiated in the Gl)
Central nervous system infections
Infections of the skin (such as mucocutanous candidiasis)
The peptides, medicinal products and methods according to the invention may either be used alone, in combination with each other or in combination with conventional therapy.
According to the present invention it is also possible to include the peptides, in an effective amount, in any kind of food or beverage intended to reduce infections and/or inflammations in patients running an increased risk of such conditions due to an underlying disease, a low birth weight or a medical treatment. For example, it is possible to include the peptides, in an effective amount, in an infant formula food intended to inhibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants. When the peptides according to the invention is to be used in food stuffs, e. g. for nutritional purposes, it is especially preferred to use peptides of natural origin.
Since the peptides according to the invention have antimicrobial effects they can also be used as preservatives in different food stuffs and medicinal products such as gels, creams, ointments, pastes, solutions, emulsions etc.
The invention will now be further explained in the following examples. These examples are only intended to illustrate the invention and should in no way be considered to limit the scope of the invention.
Brief description of the drawings
Figure 1. Growth inhibition of E.coli 'm the presence of HLBDargi and a 23-a.a. long peptide (amino acids 18 to 40 of hl_F). Using a peptone medium (1%) the microplate was incubated over night and read spectrophotometrically at 650 nm. As can be seen a concentration of 12.5 μg/ml totally reduced the growth. Figure 2. A) The number of S. aureus located in the joints of peptide-treated and vehicle treated animals. B) The distribution of animals with a scoring of 3 or more (the most severe inflammation and/or erosion of joint tissue was scored as 5, and no histological changes as 0). A dose of 2x10" S.aureus and 100 μg of peptide (HLBDargi) were injected.
Figure 3. Effects of peptide treatment in Candida skin infection (quadruple spots for each peptide). The treatment dose was 400 μg per infected area. The arginine containing peptide reduced C.albicans to a higher degree than a longer peptide sequence based on the antimicrobial region in LF (peptide 25 a.a. = peptide corresponding to amino acids 16-40 of hLF).
Figure 4. Inhibitory activity of a lactoferrin-derived (HLBD1 Arg rak) peptide on IL-1- induced IL-6 (A) or PAI-1 (B) production in MeT- 5A cells. Indicated peptide concentrations were added to cells in triplicate (n=3) immediately after the addition of IL-I , the cell supernatants were collected after 3 hours (in A) or 6 hours (in B) of incubation and analyzed for IL-6 (in A) or PAI-1 (in B) by quantitative ELISA. The results are expressed in relation to the IL-6 level (288 pg/ml) or PAI-1 level (18.3 ng/ml) obtained without any peptide added, respectively. Statistical differences were determined by two-sided Student's t-test (* p ≤ 0.05; ** p≤ 0.01; *** ≤pθ.005; **** ≤pθ.001).
Figure 5. Dose-inhibitory activity of a lactoferrin-derived peptide (HLBD1 Arg rak) on LPS-induced TNF-α secretion in human monocyte derived macrophage cell line THP- 1 cells. Indicated peptide concentrations were added to cells in triplicate (n=3) 30 min after the addition of LPS (0.1 ng/ml). TNF-α levels at 6 h after the stimulation were measured by ELISA (R&D Systems, Minneapolis, MN). The results are expressed in relation to TNF-α levels (290 pg/ml) obtained without any peptide added. Statistical differences among genotypes were determined by two-sided Student's t-test (* p ≤ 0.05).
Figure 6. Dose-inhibitory activity of lactoferrin-derived peptides on IL-1β-induced IL-6 (A) or PAI-1 (B) production in MeT-5A cells. Indicated peptide concentrations were added to cell in triplicate (n=3) immediately after the addition of IL-1 β, the cell supernatants were collected after 3 hours (in A) or 6 hours (in B) of incubation and analyzed for IL-6 (in A) or PAI-1 (in B) by quantitative ELISA. The results are expressed in relation to the IL-6 level (1770 pg/ml) or PAI-1 level (63.0 ng/ml) obtained without any peptide added Statistical differences were determined by two- sided Student's t-test (* p ≤ 0.05;) ♦ = HLBDargirak, A= PXL11, x = PXL12, ■ = PXL 13, « = PXL14
Figure 7. Dose-inhibitory activity of of lactoferπn-deπved peptides on LPS-induced TNF-α secretion in human monocyte derived macrophage cell line THP-1 cells
Indicated peptide concentrations were added to cells in triplicate (n=3) 30 min after the addition of LPS (0 1 ng/ml) TNF-α levels at 6 h after the stimulation were measured by ELISA (R&D Systems). The results are expressed in relation to TNF-α levels (273-775 pg/ml) obtained with peptide added at 10 μg/ml. Statistical differences were determined by two-sided Student's t-test (* p ≤ 0.05;). ♦ = HLBDargirak, A= PXL11 , X = PXL12, ■ = PXL13, • = PXL14
Examples
Example 1. Antimicriobial assay
Arg-Arg-Arg-Arg- or Arg-Arg-Arg- containing peptides (Table 1) have been analysed by an antimicrobial assay using E.coli, S.aureus and C.albicans as test microorganisms.
Washed cells were suspended in 1 % Bactopeptone (BP)(Difco, USA). The concentration of bacterial or fungal cells was spectrophotometrically adjusted. Peptides serially diluted in BP by twofold steps were added in duplicate or triplicate to the wells of a microtiterpiate (200 μl per well). The bacterial or yeast cell solutions were added in 10 μl volumes to give a final concentration of approximately 2 x 105 cells per ml. The concentration of the stock solution was always checked by viable counts. The microplate was incubated at 370C in a humid chamber for 2 h unless otherwise stated. Five μl were taken from each well and added as a drop onto a blood agar plate and incubated over night at 37°C.
The concentration of lactoferrin or peptide causing a 99% reduction of the inoculum was defined as the MMC99.
The microbicidal activity of the peptides showed that all peptides were better than the natural sequence amino acids 1-31 (HLBD31) except for HLBDarg2 (Table 2). In this peptide the Arg-Arg-Arg-Arg-Arg sequence was linked to phenylalanine from the amino-terminal side via a spacer (three glycine residues).
In Figure 1 the growth inhibition of HLBDargi was compared with a native lactoferrin- derived peptide HLBD2 consisting of amino acids 18 to 40. A much stronger antimicrobial activity was recorded for HLBDargi in this medium which strongly reduces the antimicrobial activity of many other LF derived peptides. able 1 Arginine-tailed peptides used i n the Examples
Figure imgf000020_0001
Cm is acetamidomethyl-cysteine
Table 2
MMC99, μg/ml
C. albicans S. aureus E.coli
5 peptide 2 h 24 h 2 h 24 h 2 h 24 h
HLBDargi 6 .3 10 12 19 17 3.1
10 HLBDargδ 12 12 25 25 25 6
HLBDargioptC 12 21 25 25 19 6
15 HLBDarg1optC(K24) <50 ≤50 16 12 12 6
HLBD2optCarg1 12 25 25 25 25 12
HLBDargirak ND ND 12 19 12 6 on
HLBDarg2 >100 >100 >100 >100 >100 >100
HLBD31 25 38 100 100 >100 50
*ND= not determined
ExamDle 2. Staphylococcus aureus joint infection.
Mice. 5 to 8-week old mice were obtained from B&K (Sollentuna, Sweden) and 30 maintained in the animal facility of the Department of Rheumatology, University of Gδteborg. They were housed 10 per cage under standard conditions of temperature, and light and fed standard chow and water ad libitum.
Bacterial strain and infection. S. aureus strain AB-1 was used. The bacteria were injected into the both knee joints (synovial space) of the hind paw. Immediately before
35 injection, bacteria and peptide or vehicle only were mixed. A dose of 2x104 $. aureus and 100 μg of peptide (HLBDargi) were injected. The knee of the right hind paw was used as positive control Also some animals were injected with peptide solution only. The animals were killed at day 3 after infection and the knee joints were fixed in formaline and decalcified for histological evaluation. The number of bacteria present in
40 the left joint was analysed by culturing (cotton swab of joint fluid after removal of skin).
The numbers of S. aureus in the joint were higher in the vehicle treated group although no statistical significance was established (Figure 2). The blind scoring of the joints revealed significant differences between peptide-treated and vehicle treated animals. Thus the peptide appeared to reduce the severity of the Staphylococcus- induced arthritis.
Example 3. Candida albicans skin infection
Candida albicans. The yeast cells (ATCC64549) were incubated over night in Sabourad broth at 230C. The cells were washed in phosphate buffer (10 mM, pH 7.4) and adjusted to a concentration of 2x1010ZmI.
Skin infection and peptide treatment. Mice were treated with C. albicans on a shaved area (2x10s yeast cells per spot) by gentle rubbing a volume of 10 μl with a blunt plastic rod during anaesthesia. The following day anaesthetized mice were treated with 10 or 20 μl of a peptide solution or vehicle (phosphate buffer) by applying the volume onto the infected spots. The solution was allowed to dry. After 4 h the treatment was repeated. The day after the animals were killed. Viable counts were performed on washings, obtained from the treated areas by using a metal ring placed over the spot and gentle rubbing in the presence of 100 μl of phosphate buffer containing Triton-x 100 (0.01%). At most three different concentrations of the peptide were used, starting with 400, 100, and 25 μg per spot. Although a high variability was obtained (quadruple spots for each concentration), a clear reduction of colony-forming units (CFU) is obtained with the three peptides (Table 3). The results obtained with 400 μg are presented in Figure 3.
Table 3.
Candida albicans peptide no. of CFU (mean ±SE) CFU(mean ±SE) p value experiments treatment vehicle
HLBDargi 3 40±10 166±33 0.0066 HLBDargirak 2 105±28 414±60 0.0004 HLBDargδ 1 12±8.3° 43+3 0.024 ° 1 mg per spot
Example 4. In vitro anti-inflammatory and fibrinolytic effect
The MeT- 5A cell line corresponding to normal human mesothelial cells was maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF; AMS Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA Laboratories GmbH) and 870 nM human recombinant insulin (Sigma). The cells were induced by addition of recombinant IL-1 (R&D Systems), 0.1 or 0.5 ng/ml in the case of the IL-6 or PAI- 1 assay, respectively, into the medium specified above except of containing 5% heat inactivated FBS. The given concentration of peptide HLBD1 Arg rak was added immediately after stimulation by IL-1
IL-6 production was measured 3 hours after induction by quantitative immunoassay ELISA using human monoclonal anti-IL-6 antibody (R&D Systems).
PAI-1 levels were measured 6 hours after induction by commercially available ELISA kit (Tint-Eliza PAI-1 , Trinity Biotech).
The results are expressed in relation to the IL-6 (288 pg/ml) or PAI-1 levels (18.3 ng/ml) obtained without any peptide added
The results (Figure 4) indicate that IL-6 and PAI-1 production in mesothelial cells is significantly down regulated by the peptide.
Example 5. In vitro anti-inflammatory effect
The THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was maintained in RPM1 1640 (PAA Laboratories GmbH) supplemented with 10% fetal bovine serum (FBS1 PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES (PAA). The cell density was adjusted to 1 x106 cells/ml and 500 μl of the cell suspension was added to 24-well cell culture plates (Sarstedt) The cells were treated with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48 hours to differentiate the monocytes into macrophage-like cells. After 48 hours the cells were stimulated by addition of 0.1 ng/ml LPS (E. coll serotype 055 B5; Sigma) into the medium specified above except of containing 5% heat inactivated FBS. The given concentration of peptide HLBD1 Arg rak was added 30 minutes after addition of LPS. The cell supernatants were collected after 6 hours of incubation, ceπtrifuged and analyzed for TNF-α production by ELISA (R&D Systems).
The results (Figure 5) of the experiment demonstrate that TNF-α production in human monocyte derived macrophages is significantly down regulated by the peptide.
Example 6. In vitro anti-inflammatory and fibrinolytic effect The MeT-5A cell line corresponding to normal human mesothelial cells was maintained in M199 medium (GIBCO) supplemented with 10% fetal bovine serum (FBS1 PAA Laboratories GmbH), 3.3 nM epidermal growth factor (EGF, AMS Biotechnology Ltd), 400 nM hydrocortisone (MP Biomedicals), 20 mM Hepes (PAA Laboratories GmbH) and 870 nM human recombinant insulin (Sigma). The cell density was adjusted to 1.6x105 cells/ml and 100 μl of the cell suspension was added per well to 96-well cell culture plates (Sarstedt). The cells were incubated for 48 hours to allow cells to attach and grow to confluence. After 48 hours the cells were induced by addition of recombinant IL-1 β (R&D Systems), 0 1 or 0 5 ng/ml in the case of the IL-6 or PAI-1 assay, respectively, into the medium specified above except of containing 5% heat inactivated FBS The given concentrations of the different peptides were added immediately after stimulation by I L- 1 β
The cell supernatants were collected after 3 or 6 hours of incubation and analyzed for IL-6 or PAI-1 by ELISAs specific for IL-6 (R&D Systems) or for PAI-1 (Tint-Eliza PAI-1 , Trinity Biotech), respectively
The results (Figure 6) indicate that IL-6 and PAI-1 production in mesothelial cells is significantly down regulated by the peptides.
Example 7 In vitro anti-inflammatory effect The THP-1 cell line (ATCC #TIB-202) corresponding to human monocytes was maintained in RPMI 1640 (PAA Laboratories GmbH) supplemented with 10% fetal bovine serum (FBS, PAA), 1 mM Sodium Pyruvate (Sigma), and 20 mM HEPES (PAA) The cell density was adjusted to 1x10e cells/ml and 100 μl of the cell suspension was added per well to 96-well cell culture plates (Sarstedt) The cells were treated with 10 ng/ml PMA (phorbol 12-myristate 13-acetate; Sigma) for 48 hours to differentiate the monocytes into macrophage-like cells After 48 hours the cells were stimulated by addition of 0 1 ng/ml LPS (E coll serotype 055 B5; Sigma) into the medium specified above except of containing 5% heat inactivated FBS The indicated concentrations of the different peptides were added 30 mm after addition of LPS The cell supernatants were collected after 6 hours of incubation, centrifuged and analyzed for TNF-α production by ELISA (R&D Systems)
The results (Figure 7) of the experiment demonstrate that TNF-α production in human monocyte derived macrophages is significantly down regulated by the peptides Example 8. Antimicrobial assay
Arg-Arg-Arg-Arg-Arg-Arg- or Arg-Arg-Arg-Arg-Arg- containing peptides (Table 4) have been analysed by an antimicrobial assay using E.coli, S.aureus and P. aeruginosa as test microorganisms. Cells were suspended in 1% Brain-heart infusion medium (BHI)(Difco, USA). The concentration of bacterial cells was spectrophotometrically adjusted. Peptides serially diluted in 1% BHI by twofold steps were added in duplicate to the wells of a microtiterplate (100 μl per well). The bacterial solutions were added in 5 μl volumes to give a final concentration of approximately 5 x 105 cells per ml. The concentration of the stock solution was always checked by viable counts. The microtiterplate was incubated at 37°C for two hours. Five μl were taken from each well and added as a drop onto a blood agar plate and incubated over night at 37CC.
The concentration of peptide causing a 99% reduction of the inoculum was defined as the MMC99.
Table 4
MMC99, μg/ml peptide S. aureus E. coli P. aeruginosa
PXL11 6.3 1.6 3.1
PXL 12 6.3 1.6 3.1
PXL 13 6.3 1.6 6.3
PXL15 6.3 1.6 3.1
HLBDargirak 6.3 3.1 6.3

Claims

1. A peptide according to formula (I)
R1 -Phe-X1 -X2-X3-X4-X5-X6-X7-Lys-Val-Arg-X8-R2
I a R3 Formula (I) wherein amino acid X1 is GIn or Ala, amino acid X2 is Trp or Leu, amino acid X3 is GIn1 Ala, Om, NIe or Lys, amino acid X4 is Arg, Ala or Lys, amino acid X5 is Asn, Ala, Om or NIe, amino acid X6 is Met, Ala or Leu, amino acid X7 is Arg, Ala or Lys, amino acid X8 is GIy, Lys, GIu or Asp; when X8 is GIy then R3 is Ser-(Arg)n-X9 and the bond α is a peptide bond between the carboxyl group of GIy and the amino group of Ser; when X8 is Lys then R3 is X9-(Arg)n-Ser and the bond α is an amide bond between the ε-amino group in Lys and the carboxyl group in Ser; and when X8 is GIu or Asp then R3 is Ser-(Arg)n-X9 and the bond α is an amide bond between the γ-carboxyl group of GIu or the β-carboxyl group of Asp and the amino group of Ser; amino acid X9 is either no amino acid or GIy, and n is an integer from 1 to 10, preferably an integer from 2 to 6, preferably an integer from 4 to 6, or even more preferably an integer from 3 to 4; R1 is either no amino acid, Cys or a peptide sequence selected from the peptides SEQ ID NO: 3 and N-terminally truncated fragments thereof including
Gly-Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Arg-Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Arg-Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys, Arg-Arg-Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Arg-Ser-Val-Gln-Tφ-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Ser-Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Val-Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Gln-Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys, Trp-Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Cys-Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Ala-Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Val-Ser-Gln-Pro-Glu-Ala-Thr-Lys-Cys, Ser-GIn-Pro-Glu-Ala-Thr-Lys-Cys,
Gln-Pro-Glu-Ala-Thr-Lys-Cys,
Pro-Glu-Ala-Thr-Lys-Cys,
Glu-Ala-Thr-Lys-Cys, Ala-Thr-Lys-Cys,
Thr-Lys-Cys, and
Lys-Cys,
R2 is either no amino acid, Pro or a peptide sequence selected from SEQ ID NO: 4 or C-terminally truncated fragments thereof including
Pro-Pro-Val-Ser-Cys-lle-Lys-Arg,
Pro-Pro-Val-Ser-Cys-lle-Lys,
Pro-Pro- Val-Ser-Cys-I Ie,
Pro-Pro-Val-Ser-Cys, Pro-Pro-Val-Ser,
Pro-Pro-Val, and
Pro-Pro,
2. A peptide according to claim 1 , wherein amino acid X8 is GIy and R3 is Ser-(Arg)n- X9 and the bond α is a peptide bond between the carboxyl group of GIy and the amino group of Ser
3. A peptide according to claim 1, wherein amino acid Xδ is Lys and R3 is X9-(Arg)n- Ser and the bond α is an amide bond between the ε-amino group in Lys and the carboxyl group in Ser
4. A peptide according to claim 1 , wherein amino acid Xδ is GIu and R3 is Ser-(Arg)n- X9 and the bond α is an amide bond between the γ-carboxyl group in GIu and the amino group in Ser.
5 A peptide according to any of claims 1 to 4, wherein amino acid X1 is GIn, amino acid X2 is Trp, amino acid X3 is GIn or Lys, amino acid X4 is Arg, amino acid X5 is Asn or Ala, amino acid X6 is Met, and amino acid X7 is Arg.
6 A peptide according to any of claims 1 to 5, wherein ammo acid X9 is GIy.
7 A peptide according to any of claims 1 to 6, wherein R1 is either no amino acid or the peptide sequence Ala-Thr-Lys-Cys
8. A peptide according to any of claims 1 to 7, wherein R2 is either no amino acid or the peptide sequence Pro-Pro- Val-Ser-Cys-lle-Lys-Arg.
9. A peptide according to any of claims 1 to 8, wherein a free COOH at a carboxy terminal end has been transformed into CONH2.
10. A peptide according to any of claims 1 to 8, wherein a free NH2 group at an amino terminal end has been transformed into the amide CH3CONH.
11. A peptide according to any of claims 1 to 8, wherein the amino acid Cys, if present, has been replaced by an acetamidomethyl-cysteine.
12. A peptide which is selected from Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH2
(SEQ ID NO: 5);
Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH2; (SEQ ID NO: 6);
Ac-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH2
(SEQ ID NO: 7);
Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NH2
(SEQ ID NO: 8);
Ac-Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NHj (SEQ ID NO: 9); and
Ala-Thr-Lys-CysM- -Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Gly-Ser-Arg-Arg-Arg-Arg-Gly-NHz
(SEQ ID NO: 10).
13. A peptide which is selected from
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2 ;
I Gly-Arg-Arg-Arg-Ser Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2 ;
I Gly-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2 ;
I Gly-Arg-Arg-Arg-Arg-Ser
Ac-Phe-GIn-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NHa ; I
Gly-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2 ;
I Gly-Arg-Arg-Arg-Arg-Ser
AIa-Th r-Lys-CysM-
-Phe-GIn-Trp-GIn-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg ;
I Gly-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg ;
I Gly-Arg-Arg-Arg-Arg-Ser
Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2 ;
I G ly-Arg-Arg-Arg-Arg-Ser
Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg ;
I Gly-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg ;
I Gly-Arg-Arg-Arg-Arg-Ser
Ala-Thr-Lys-CysM- -Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Lys-NH2 ;
I Gly-Arg-Arg-Arg-Arg-Ser Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2
I Ac-Gly-Arg-Arg-Arg-Arg-Arg-Ser
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Lys-NH2
I Ac-Gly-Arg-Arg-Arg-Arg-Arg-Arg-Ser
and Ac-Phθ-Gln-Trp-Gln-Arg-Asn-Mθt-Arg-Lys-Val-Arg-Lys-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg-NHa
I Ac-G ly-Arg-Arg-Arg-Arg-Arg-Ser
14. A peptide which is selected from
Ac-Phe-Gln-Trp-Gln-Arg-Asn-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2 ;
Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2 ;
Ac-Phe-Gln-Trp-Lys-Arg-Asn-Met-Arg-Lys-Val-Arg-Glu-NH2 I
Ser-Arg-Arg-Arg-Arg-Gly-NH2 ,
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2 ;
Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-GIn-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg;
I Ser-Arg-Arg-Arg-Arg-Gly-NH2
Ac-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg;
I Ser-Arg-Arg-Arg-Arg-Gly-NH2 Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Gln-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2 ;
Ala-Thr-Lys-CysM-
-Phe-GIn-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg;
I Ser-Arg-Arg-Arg-Arg-Gly-NH2
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-Pro-Pro-Val-Ser-CysM-lle-Lys-Arg;
I Ser-Arg-Arg-Arg-Arg-Gly-NH ;
Ala-Thr-Lys-CysM-
-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Gly-NH2;
and
Ac-Phe-Gln-Trp-Lys-Arg-Ala-Met-Arg-Lys-Val-Arg-Glu-NH2
I Ser-Arg-Arg-Arg-Arg-Arg-Arg-Gly-NH2
15. A pharmaceutical composition comprising a peptide according to any of the claims 1 to 14.
16. A pharmaceutical composition according to claim 15 for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars.
17. A pharmaceutical composition according to any one of the claims 15 to 16 formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.
18. Food stuff comprising a peptide according to any of the claims 1 to 14.
19. Use of a peptide according to any one of the claims 1 to 14 for the production of a medicinal product for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars.
20. Use according to claim 19, wherein the medicinal product is formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.
21. A method for treatment or prevention of infections, inflammations, tumours, pain, wounds and scars wherein an effective amount of a peptide according to any of claims 1 to 14, fragments, and functionally equivalent homologues and analogues thereof, is administered to a patient.
22. A method according to claim 21, wherein the substance is orally, systemically, parenterally, locally or topically administered.
23. A method according to claim 22, wherein the substance is included in a food stuff.
24. A method according to claim 23, wherein the substance is included in an infant formula food.
25. A peptide according to any one of the claims 1 to 14 for use as a medicament.
26. A peptide according to any one of the claims 1 to 14 for the treatment and/or prevention of infections, inflammations, tumours, pain, wounds and scars.
27. A peptide according to claim 26, formulated for oral administration, systemic administration, parenteral administration, local administration or topical administration.
PCT/EP2008/065186 2007-11-14 2008-11-10 New synthetic arginine substituted peptides and their use WO2009062898A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2008323041A AU2008323041A1 (en) 2007-11-14 2008-11-10 New synthetic arginine substituted peptides and their use
JP2010533548A JP2011503137A (en) 2007-11-14 2008-11-10 Novel arginine substituted peptides and uses thereof
MX2010005280A MX2010005280A (en) 2007-11-14 2008-11-10 New synthetic arginine substituted peptides and their use.
CN200880114504.9A CN101878226B (en) 2007-11-14 2008-11-10 New synthetic arginine substituted peptides and their use
CA2703894A CA2703894A1 (en) 2007-11-14 2008-11-10 New synthetic arginine substituted peptides and their use
EP08850370.1A EP2212352B1 (en) 2007-11-14 2008-11-10 New synthetic arginine substituted peptides and their use
DK08850370.1T DK2212352T3 (en) 2007-11-14 2008-11-10 Novel synthetic arginine-substituted peptides and their use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07120713.8 2007-11-14
EP07120713A EP2060586A1 (en) 2007-11-14 2007-11-14 New synthetic arginine substituted peptides and their use
US99006607P 2007-11-26 2007-11-26
US60/990,066 2007-11-26

Publications (1)

Publication Number Publication Date
WO2009062898A1 true WO2009062898A1 (en) 2009-05-22

Family

ID=39226731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/065186 WO2009062898A1 (en) 2007-11-14 2008-11-10 New synthetic arginine substituted peptides and their use

Country Status (9)

Country Link
US (2) US7928185B2 (en)
EP (2) EP2060586A1 (en)
JP (1) JP2011503137A (en)
CN (1) CN101878226B (en)
AU (1) AU2008323041A1 (en)
CA (1) CA2703894A1 (en)
DK (1) DK2212352T3 (en)
MX (1) MX2010005280A (en)
WO (1) WO2009062898A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481751A1 (en) 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
WO2014174517A1 (en) * 2013-04-25 2014-10-30 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2893120C (en) * 2012-12-11 2022-03-15 Imaxio Modified coiled coil type proteins having improved properties
AU2014234363B2 (en) * 2013-03-18 2018-02-15 Osivax Sas Influenza nucleoprotein vaccines

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034641A2 (en) * 1999-11-11 2001-05-17 Am-Pharma B.V. Antimicrobial activity of the first cationic cluster of human lactoferrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2818056B2 (en) * 1990-09-07 1998-10-30 森永乳業株式会社 Antimicrobial peptides and antimicrobial agents
DE69220679T2 (en) 1992-01-23 1997-10-23 Morinaga Milk Industry Co Ltd ANTIBACTERIAL AGENT AND TREATMENT OF ITEMS WITH THIS
JP3347819B2 (en) 1993-06-28 2002-11-20 森永乳業株式会社 Purification method of antimicrobial peptide
JP3529423B2 (en) 1994-04-01 2004-05-24 森永乳業株式会社 Method for producing antimicrobial peptide
JP3812957B2 (en) 1994-08-02 2006-08-23 森永乳業株式会社 Corneal injury treatment agent
JPH08143468A (en) 1994-11-17 1996-06-04 Morinaga Milk Ind Co Ltd Antiulcer agent
AU3872797A (en) 1996-08-12 1998-03-06 A+ Science Invest Ab Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin
SE9804614A0 (en) * 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
WO2006047744A2 (en) 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034641A2 (en) * 1999-11-11 2001-05-17 Am-Pharma B.V. Antimicrobial activity of the first cationic cluster of human lactoferrin

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AZUMA M ET AL: "Antibacterial activity of multiple antigen peptides homologous to a loop region in human lactoferrin", JOURNAL OF PEPTIDE RESEARCH, vol. 54, no. 3, September 1999 (1999-09-01), pages 237 - 241, XP002475047, ISSN: 1397-002X *
BERKEL VAN P H C ET AL: "N-TERMINAL STRETCH ARG2, ARG3, ARG4 AND ARG5 OF HUMAN LACTOFERRIN IS ESSENTIAL FOR BINDING TO HEPARIN, BACTERIAL LIPOPOLYSACCHARIDE, HUMAN LYSOZYME AND DNA", BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 328, 15 November 1997 (1997-11-15), pages 145 - 151, XP002072084, ISSN: 0264-6021 *
MORIARTY L C ET AL: "Factors contributing to the potency of antimicrobial cationic peptides from the N-terminal region of human lactoferrin", FEMS MICROBIOLOGY LETTERS, AMSTERDAM, NL, vol. 239, no. 2, 15 October 2004 (2004-10-15), pages 295 - 299, XP004597837, ISSN: 0378-1097 *
ODELL E W ET AL: "ANTIBACTERIAL ACTIVITY OF PEPTIDES HOMOLOGOUS TO A LOOP REGION IN HUMAN LACTOFERRIN", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 382, 1996, pages 175 - 178, XP002921040, ISSN: 0014-5793 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012210564B2 (en) * 2011-01-26 2016-10-27 Pergamum Ab Human lactoferrin based peptides having antiinflammatory activity
WO2012101156A2 (en) 2011-01-26 2012-08-02 Pharmasurgics In Sweden Ab New synthetic peptides and their use
WO2012101157A1 (en) 2011-01-26 2012-08-02 Pharmasurgics In Sweden Ab Human lactoferrin derived peptides and there use
JP2014505062A (en) * 2011-01-26 2014-02-27 ペルガモン アクティエボラーグ Human lactoferrin-derived peptide and use thereof
JP2014505061A (en) * 2011-01-26 2014-02-27 ペルガモン アクティエボラーグ Novel synthetic peptides and their use
US8846608B2 (en) 2011-01-26 2014-09-30 Pergamum Ab Human lactoferrin derived peptides and their use
US9132165B2 (en) 2011-01-26 2015-09-15 Pergamum Ab Synthetic peptides and their use
RU2596393C2 (en) * 2011-01-26 2016-09-10 Пергамум АБ Novel synthetic peptides and use thereof
EP2481751A1 (en) 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
AU2012210565B2 (en) * 2011-01-26 2017-03-30 Pergamum Ab Human lactoferrin derived peptides and there use
KR101933900B1 (en) 2011-01-26 2018-12-31 페르가뭄 아베 Human lactoferrin derived peptides and there use
WO2014174517A1 (en) * 2013-04-25 2014-10-30 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
US9850278B2 (en) 2013-04-25 2017-12-26 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof

Also Published As

Publication number Publication date
US7928185B2 (en) 2011-04-19
US20110224152A1 (en) 2011-09-15
CN101878226A (en) 2010-11-03
EP2212352B1 (en) 2014-07-02
EP2212352A1 (en) 2010-08-04
MX2010005280A (en) 2010-08-31
CA2703894A1 (en) 2009-05-22
DK2212352T3 (en) 2014-09-29
US8815812B2 (en) 2014-08-26
CN101878226B (en) 2014-06-25
EP2060586A1 (en) 2009-05-20
US20090186823A1 (en) 2009-07-23
AU2008323041A1 (en) 2009-05-22
JP2011503137A (en) 2011-01-27

Similar Documents

Publication Publication Date Title
EP2668204B1 (en) Human lactoferrin based peptides having antiinflammatory activity
JP4488622B2 (en) Peptides based on human lactoferrin sequences and uses thereof
AU2012210564A1 (en) Human lactoferrin based peptides having antiinflammatory activity
AU2012210565A1 (en) Human lactoferrin derived peptides and there use
US8815812B2 (en) Synthetic arginine substituted peptides and their use
US20110053833A1 (en) Synthetic peptides and their use
WO2012011848A1 (en) Polypeptide having antibacterial activity and suitable for producing drugs for the treatment of bacterial infections in humans
Ramos Recombinant expression and activity of cationic antimicrobial peptides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114504.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08850370

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2756/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008323041

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2703894

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008850370

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010533548

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/005280

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008323041

Country of ref document: AU

Date of ref document: 20081110

Kind code of ref document: A